ASX Release

Prescient to Resume Clinical Trial of PTX-200 in Ovarian Cancer

- US FDA has lifted the clinical hold on PTX's Phase 1b trial in Ovarian Cancer
- Modifications have been made to trial inclusion criteria and protocols
- PTX to resume trial recruitment

Melbourne, Australia (6 November 2017): Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX; Prescient) is pleased to announce the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Company's Phase 1b trial of PTX-200 in patients with platinum resistant ovarian cancer. Prescient is now preparing to resume recruitment of patients in this trial.

As previously announced, Prescient paused its three clinical trials of PTX-200 following a serious adverse event in a patient with late stage breast cancer who experienced liver failure and passed away. These severe adverse event are not unusual in oncology clinical studies where patients are very ill and where existing standard therapies can have potentially serious adverse effects.

Prescient has responded to the FDA's requests for the ovarian cancer trial, including an updated risk mitigation plan, to the FDA's satisfaction, and removal of the clinical hold allows the trial to resume. This development follows the FDA lifting the clinical hold on the Company's trial of PTX-200 in patients with refractory or relapsed Acute Myeloid Leukemia (AML), announced on September 4.

The remaining clinical hold is the PTX-200 trial in patients with metastatic and locally advanced HER2 negative breast cancer, which Prescient is addressing. This trial had successfully completed the Phase 1b study prior to it being placed on hold.

Prescient's CEO and Managing Director, Steven Yatomi-Clarke said, "We are pleased to resume our trial of PTX-200 in ovarian cancer, which represents a significant unmet medical need, particularly for women affected by platinum resistant forms of the disease. Our team is addressing our last remaining clinical hold, and will continue to work with the FDA in a similar process until it is resolved.

In the meantime, Prescient has a busy and exciting schedule of clinical activity with PTX-200 in AML and ovarian cancer, as well as activities for PTX-100 in RhoA mutant lymphomas."

ENDS

About Prescient Therapeutics Limited (Prescient)

Prescient is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Prescient's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials. The first is a Phase 1b/2 trial evaluating PTX-200 as a new therapy for relapsed and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt); Yale Cancer Center in New Haven, Connecticut (Yale) and Kansas University Medical Center (KUMC) under the leadership of Professor Jeffrey Lancet, MD.

Prescient is also conducting a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt, currently on clinical hold. The third trial is a Phase 1b/2 trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

Prescient's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It inhibits the activation of Rho, Rac and Rho circuits in cancer cells, which act as key oncogenic pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors and will be the focus of studies in rare hematological malignancies, namely RhoA mutant lymphomas.

Further enquiries:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited
+61 417 601 440

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
+61 401 018 828

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally,

and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.